Medicine once-daily.

Alkermes reports topline outcomes from phase 2 research of ALKS 5461 medication for major depressive disorder Alkermes plc today announced positive preliminary topline outcomes from a phase 2 study of ALKS 5461, its novel drug substance for major depressive disorder in patients who have an inadequate response to regular therapies for clinical depressive disorder. ALKS 5461 reflects a fresh approach to the treatment of MDD based on modulation of opioid receptors in the brain and was created as a non-addictive, oral, medicine once-daily. Data from the study showed that ALKS 5461 significantly decreased depressive symptoms across a variety of standard measures including the research's primary final result measure, the Hamilton Despair Rating Scale >rd Annual New Clinical Medication Evaluation Unit Meeting in Hollywood, Fla ., May 28-31, 2013.